Ad
related to: castration resistant cancer prognosis life expectancy- Dosing & Administration
Download Patient Brochure and
View Dose Modifications
- Important Safety Info
Safety Profile & Adverse Reactions
For XTANDI® (enzalutamide).
- Clinical Trial Data
View Clinical Data & Results
From a Pivotal Trial for XTANDI®
- XTANDI® FAQs For HCPs
Explore FAQs for Providers & Better
Prepare Your Patients.
- Dosing & Administration
Search results
Results from the WOW.Com Content Network
Prostate cancer is the second-most frequently diagnosed cancer in men, and the second-most frequent cause of cancer death in men (after lung cancer). [ 2 ] [ 3 ] Around 1.2 million new cases of prostate cancer are diagnosed each year, and over 350,000 people die of the disease, annually. [ 2 ]
This combination likely improves overall and cancer-specific survival by slowing the spread of the cancer. However, taxane-based chemotherapy may cause an increase in side effects. [45] Medications that block the production of adrenal androgens such as DHEA include ketoconazole and aminoglutethimide. Because the adrenal glands make only about 5 ...
Darolutamide, sold under the brand name Nubeqa, is an antiandrogen medication which is used in the treatment of non-metastatic castration-resistant prostate cancer in men. [8] [4] [5] [9] [10] It is specifically approved to treat non-metastatic castration-resistant prostate cancer (nmCRPC) in conjunction with surgical or medical castration. [4]
Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. [2] [9] It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), [2] nonmetastatic castration-resistant prostate cancer, [2] and metastatic castration-sensitive prostate ...
Lutetium (177 Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). [5] [6] Lutetium (177 Lu) vipivotide tetraxetan is a targeted radioligand therapy. [6] [8]
Cancer Stem Cell phenotypes are associated with disease recurrence, metastasis, and cell survival in circulation as Circulating tumor cells. Thus, activation of these programs via inhibition of the androgen axis provides a mechanism by which tumor cells can adapt to promote disease recurrence and progression.
The American Cancer Society reports 5-year relative survival rates of over 70% for women with stage 0-III breast cancer with a 5-year relative survival rate close to 100% for women with stage 0 or stage I breast cancer. The 5-year relative survival rate drops to 22% for women with stage IV breast cancer. [3]
Satraplatin has been developed for the treatment of men with castrate-refractory, metastatic prostate cancer for several reasons. Its relative ease of administration, potential lack of cross-resistance with other platinum agents, clinical benefits seen in early studies of prostate cancer, and an unmet need in this patient population after Docetaxel failure at that time.
Ad
related to: castration resistant cancer prognosis life expectancy